In young women with breast cancer, rates of BRCA1 and BRCA2 mutation testing are increasing as a means to evaluate how concerns about genetic risk and use of genetic information affect subsequent treatment decisions. This according to a study of 897 women aged ≤40 years with breast cancer diagnosis. Researchers found:
• 87% of women reported BRCA testing by 1 year after breast cancer diagnosis, with frequency of testing increasing among women diagnosed from Aug. 1, 2006, through Dec. 31, 2013.
• Of 39 women diagnosed with breast cancer in 2006, 30 (76.9%) reported testing.
• In 2007, a slightly lower percentage of women (70.2%) reported testing; however, the proportion tested increased each subsequent year.
• Among untested women, 37 (31.6%) of 117 did not report discussion of the possibility that they might have a mutation with a physician and/or genetic counselor, and 43 (36.8%) of 117 were considering future testing.
• 248 (29.8%) of 831 women said that knowledge or concern about genetic risk influenced surgical treatment decisions.
Citation: Rosenberg SM, Ruddy KJ, Tamimi RM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. [Published online ahead of print February 11, 2016]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.5941.